Oncology

 

Evotec has a long history of contributing to the oncology field through partners, achieving numerous oncology milestones including multiple PDCs, 14 clinical drugs and 1 marketed product.

Our dedicated oncology team assists pharmaceutical, biotech, not-for-profit and academic organisations in their drug discovery research activities offering a comprehensive panel of activities from target identification to pre-clinical candidate through a highly sophisticated and integrated drug discovery platform.

Evotec has established a leading technology platform enabling the discovery, development and clinical translation of new cancer therapies. Evotec’s expertise includes the evaluation of small molecular weight compounds, natural compounds, biologics and vaccines.

With a team of ~100 scientists dedicated to oncology, Evotec has a significant background in a broad range of scientific areas, including tumour microenvironment, immuno-oncology, signal transduction, cancer metabolism and epigenetics.

Key capabilities of Evotec’s oncology discovery platform

T-Lymphocyte panel

Previous Next Show fullscreen

Images provided by Nathalie van Acker, François-Xavier Frenois, Philippe Rochaix, Département d'Anatomopathologie, IUCT Oncopole, Toulouse, France

In vitro biology

  • Extensive expertise in molecular biology, biochemical, biophysical and cellular assay systems for oncology targets including kinases, metabolic enzymes and PPIs
  • Target identification approaches via phenotypic or CRISPR screens and chemical biology
  • Customised high-content imaging assays for phenotypic screening through to supporting lead optimisation
  • In vitro antibody evaluation know-how strongly connected with biophysical methods (antibody biochemical characterisation and efficacy evaluation)
  • Specific assays to study the microenvironment (immune cells, fibroblasts, adipocytes, endothelial cells), targeted therapy resistance, and drug impact on cancer metabolism

In vivo pharmacology

  • Establishment of PK/PD relationships using target engagement or surrogate markers
  • Syngeneic, orthotopic tumour xenografts to track anti-tumour and microenvironment effects
  • Development of novel models, as well as humanised mouse, spontaneous metastasis, angiogenesis and alopecia models
  • Histology, morphometric analysis, immune- and MS-based approaches combined with in vivo pharmacology to analyse disease-relevant biomarkers

ELISpot for IFNg production of splenocyte-derived activated T-cells

Previous Next Show fullscreen

Biomarkers

  • RNAseq and TLDA based-gene signature analysis supported by gold standard bioinformatics tools for data mining and pathways analysis
  • Leading mass spectrometry-based proteomics, metabolomics and lipidomics for target deconvolution, MoA studies and biomarker discovery
  • Establishment of protocols for transfer to the clinic, including Ventana IHC platform, FACS, ELIspot and blood biochemistry
  • Access to patient material for biomarker validation and ex vivo studies

Structure-based drug design-driven medicinal chemistry

  • Experienced structural biology, computational and medicinal chemistry teams working in synergy to optimise both orthosteric and allosteric screening hits through rapid cycle times

Additional capabilities such as Evotec’s high-throughput screening, bioinformatics research, DMPK and reagent production platforms can also be accessed to support and accelerate your oncology programmes.

Summary

  • Expertise in tumour microenvironment, immuno-oncology, signal transduction, cancer metabolism and epigenetics
  • Critical mass of > 100 scientists focussing on oncology  research
  • Biomarker discovery and validation in patient samples
  • CRISPR platform for target discovery and validation
  • Rational design of novel targeted therapies

You might also be interested in

Drug discovery services In vitro biology for oncology In vivo pharmacology for oncology EVT Innovate

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 F +44.(0)1235.86 31 39 vCard
TOP